“clinical-trials” Archives

in
Entry Author Date Location
Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals 09/14/20 Seattle
Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout 09/14/20 San Francisco
Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test 09/10/20 San Francisco
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue 09/09/20 National
Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest 09/08/20 San Francisco
Q&A: BIO CEO Michelle McMurray-Heath Outlines Diversity Goals 09/05/20 National
AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase 09/04/20 National
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More 09/04/20 National
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally 09/03/20 Boston
Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs 09/02/20 Seattle
Reeling From FDA Rejection, Intercept Pharma Slashes Headcount by 25% 09/01/20 New York
Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug 09/01/20 San Francisco
Akcea Therapeutics Is Returning to Parent Ionis Pharma in $500M Buyout 08/31/20 Boston
Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal 08/31/20 San Francisco
Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More 08/28/20 National
Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests 08/27/20 Seattle
AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial 08/27/20 New York
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases 08/26/20 Boston
Yumanity to Merge With Proteostasis to Advance Neuro Drug Pipeline 08/24/20 Boston
Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts 08/20/20 National
Alzheon Lands $47M to Take Another Shot at a Pivotal Alzheimer’s Test 08/20/20 Boston
FDA Rejects BioMarin Hemophilia Gene Therapy, Asks for More Data 08/19/20 National
J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout 08/19/20 New York
Advisory Body Backs MesoBlast Therapy for Transplant Complication 08/14/20 New York
CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears 08/14/20 Europe
Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More 08/14/20 National
With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor 08/12/20 New York
F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections 08/12/20 Europe
Pfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political 08/12/20 National
Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy 08/11/20 Europe
Page 2 of 56 « previous page · next page »